T2-"Low" Asthma: Overview and Management Strategies.
Asthma
Asthma in children
Asthma management
Biomarker
Endotype
Eosinophil
Neutrophil
Phenotype
Sensitization
Type 2 inflammation
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
19
08
2019
revised:
11
11
2019
accepted:
11
11
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
5
2021
Statut:
ppublish
Résumé
Although the term "asthma" has been applied to all patients with airway lability and variable chest symptoms for centuries, phenotypes of asthma with distinct clinical and molecular features that may warrant different treatment approaches are well recognized. Patients with type 2 (T2)-"high" asthma are characterized by upregulation of T2 immune pathways (ie, IL-4 and IL-13 gene sets) and eosinophilic airway inflammation, whereas these features are absent in patients with T2-"low" asthma and may contribute to poor responsiveness to corticosteroid treatment. This review details definitions and clinical features of T2-"low" asthma, potential mechanisms and metabolic aspects, pediatric considerations, and potential treatment approaches. Priority research questions for T2-"low" asthma are also discussed.
Identifiants
pubmed: 32037109
pii: S2213-2198(19)30941-9
doi: 10.1016/j.jaip.2019.11.006
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
452-463Subventions
Organisme : NIAID NIH HHS
ID : U19 AI077439
Pays : United States
Informations de copyright
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.